PQQ-containing composition, application thereof and skin care product

Abstract

The invention relates to the technical field of cosmetics, in particular to a composition containing PQQ, application of the composition and a skin care product. The composition of pyrroloquinoline quinone or sodium salt thereof and sodium surfactin provided by the invention has good permeability and stability, and meanwhile, has a remarkable synergistic interaction effect in the aspects of oxidation resistance, whitening, bacteriostasis and the like. Wide application prospects are realized in the field of cosmetics. The preparation method of the composition is simple in steps, easy to operate and suitable for industrial production.

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and particularly to a composition containing PQQ, its application, and skin care products. Background Art

[0002] With the rapid development of cosmetic technology, traditional cosmetic raw materials can no longer meet people's increasingly rich requirements for the efficacy of cosmetics, and it is also difficult to meet consumers' requirements for the effectiveness of specific efficacy. In the current research on cosmetic compositions, although researchers have developed various ingredient combinations to achieve multiple effects, there are many problems in their actual applications. The synergistic effect is not obvious, the interaction between different ingredients has not been fully optimized, and the maximum efficacy of each ingredient cannot be achieved, which limits the improvement of the overall efficacy of the product. In addition, there is still a large room for improvement in aspects such as the stability, safety, and absorption effect of cosmetics.

[0003] Pyrroloquinoline quinone disodium salt (PQQ-2Na) is a water-soluble vitamin-like compound with strong antioxidant activity. It can inhibit the generation of free radicals and scavenge existing free radicals, protecting cells from oxidative damage. Although PQQ-2Na has many excellent properties in terms of antioxidant and other physiological functions, its application research in the cosmetic field is significantly lagging behind. Currently, the application research of various efficacy ingredients in the cosmetic industry is constantly deepening, while the application of PQQ-2Na is still in a relatively primary stage. Especially in the research on the synergistic effect of ingredients, no substance has been found to have a synergistic effect with PQQ-2Na to further enhance its efficacy or expand its application scope. Therefore, there is still a large room for development in the research on cosmetic compositions based on PQQ-2Na that can simultaneously achieve multiple effects such as antioxidant, whitening, soothing, and antibacterial. Summary of the Invention

[0004] In view of this, the technical problem to be solved by the present invention is to provide a composition, its application, and skin care products.

[0005] The composition provided by the present invention comprises pyrroloquinoline quinone or its sodium salt and subtilisin.

[0006] The present invention combines pyrroloquinoline quinone or its sodium salt with subtilisin. Subtilisin, as a biosurfactant, can reduce the surface tension between the active ingredient and the skin. Compared with other surfactants, subtilisin can more effectively promote PQQ-2Na to penetrate the skin barrier more easily. And adding subtilisin can make pyrroloquinoline quinone or its sodium salt more stable.

[0007] In the present invention, the mass ratio of pyrroloquinoline quinone or its sodium salt to subtilosin A is (0.02~0.1):(0.05~0.5).

[0008] In the present invention, disodium pyrroloquinoline quinone (PQQ-2Na) is used to verify the efficacy of the composition.

[0009] In some embodiments, the mass ratio of disodium pyrroloquinoline quinone (PQQ-2Na) to subtilosin A is 0.02:(0.2~0.4) or 0.1:(0.05~0.5).

[0010] In specific embodiments, the mass ratio of disodium pyrroloquinoline quinone to subtilosin A is 0.02:(0.2~0.3), or 0.02:(0.3~0.4), or 0.1:(0.05~0.1), or 0.1:(0.05~0.3), or 0.1:(0.05~0.5), or 0.1:(0.1~0.3), or 0.1:(0.1~0.5), or 0.1:(0.3~0.5).

[0011] In some specific embodiments, the mass ratio of disodium pyrroloquinoline quinone to subtilosin A is 0.02:0.2, or 0.02:0.3, or 0.02:0.4, or 0.1:0.05, or 0.1:0.1, or 0.1:0.3, or 0.1:0.5.

[0012] The present invention proves through experiments that under specific ratios, disodium pyrroloquinoline quinone and subtilosin A can produce good synergistic effects in terms of antioxidant activity, inhibiting tyrosinase activity, and inhibiting harmful bacteria.

[0013] Furthermore, the present invention also provides the application of the composition in the preparation of skin care products.

[0014] In the present invention, the efficacy of the skin care products includes soothing, antioxidant, whitening, and / or antibacterial effects.

[0015] In the embodiments of the present invention, the antibacterial effect includes against Staphylococcus aureus and / or Propionibacterium acnes.

[0016] In the embodiments of the present invention, the antioxidant effect includes scavenging free radicals. In specific embodiments, the free radicals are DPPH.

[0017] In view of the functions of the composition of the present invention, it also has the effects of anti-aging, acne treatment, anti-allergy, or redness reduction.

[0018] In the embodiments of the present invention, the whitening effect includes inhibiting tyrosinase activity.

[0019] In the present invention, the skin care products include: cleansing skin care products, nursing skin care products, or beauty / cosmetic skin care products. Among them, the cleansing skin care products include at least one of facial cleanser, facial cleansing paste, makeup remover oil, makeup remover lotion, makeup remover milk, makeup remover gel, cleansing cream, cleansing honey, facial mask, bath lotion, hand sanitizer, cleansing gel, floral water, cleansing powder, and cleansing flour; the nursing skin care products include at least one of skin care cream, skin care lotion, lotion, facial toner, facial mask, skin care gel, emollient oil, massage essential oil, massage base oil, floral water, prickly heat powder, and body powder; the beauty / cosmetic skin care products include at least one of powder compact, rouge, eyeshadow, eye ointment, eyeliner, liquid eyeliner, eyebrow pencil, eyebrow powder, perfume, cologne, face powder, loose powder, concealer stick, concealer cream, liquid foundation, cream foundation, cake foundation, powder stick, blush, and powder cream.

[0020] Further, the present invention also provides a skin care product, which includes the composition and excipients as described above.

[0021] In the skin care products of the present invention, the mass fraction of the composition as described above is 0.15% - 0.6%. For example, the mass fraction of the composition as described above is 0.15%, 0.2%, 0.22%, 0.32%, 0.4%, 0.42%, or 0.6%.

[0022] In the skin care products of the present invention, the excipients include but are not limited to purified water, surfactants, humectants, thickeners, oils, fats, esters, waxes, chelating agents, antioxidants, pH regulators, preservatives, pigments, and fragrances. In specific embodiments, the excipients include pentylene glycol and water.

[0023] Even further, the present invention also provides a skin care method, which includes applying the skin care product as described above on the skin surface.

[0024] As a feasible case, the application methods of the present invention include but are not limited to smearing, spraying, wiping, dotting, patting, massaging, applying, spraying, and injecting (such as micro-needle introduction).

[0025] As a feasible case, the skin includes but is not limited to facial skin, neck skin, hand skin, arm skin, leg skin, foot skin, shoulder skin, back skin, chest skin, abdominal skin, skin around the ears, lip skin, skin around the eyes, skin in the elbow pit, knee skin, ankle skin, scalp, skin around the fingernails / toenails, areola skin, or skin in the private parts.

[0026] The present invention provides a composition of pyrroloquinoline quinone or its sodium salt and subtilisin peptone sodium, which can have good permeability and stability, and at the same time has significant synergistic effects in aspects such as antioxidant, whitening, and antibacterial. It has broad application prospects in the cosmetic field. And the preparation method of this composition has simple steps and is easy to operate, and is suitable for industrial production. Brief Description of the Drawings

[0027] Figure 1 Shows the cumulative permeability of PQQ-2Na in 24 hours; Figure 2 Shows the stimulation intensity of each group; Figure 3 Shows the tyrosinase inhibition effect and DPPH free radical scavenging effect of each group. Detailed Embodiments

[0028] The present invention provides a composition containing PQQ, its applications and skin care products. Those skilled in the art can draw on the content of this article and appropriately modify the process parameters to achieve. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are all regarded as included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and those related can obviously make changes or appropriate alterations and combinations to the methods and applications herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0029] The test materials used in the present invention are all ordinary commercially available products and can be purchased in the market.

[0030] It should be understood that in various embodiments of the present invention, the size of the serial numbers does not mean the order of execution. Some or all steps can be executed in parallel or successively, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation to the implementation process of the embodiments of the present application.

[0031] The numerical ranges and parameters involved in the present invention have been presented as accurately as possible in the specific embodiments. However, any numerical value inevitably contains standard deviations caused by individual test methods. Therefore, unless otherwise clearly stated, it should be understood that all numerical ranges or specific data used in this disclosure may have certain reasonable deviations within a certain range, such as within ±10%, ±5%, ±1% or ±0.5%.

[0032] Some cases are recorded in the embodiments and comparative examples of the present invention. Among them, the embodiments show some implementation manners of the present invention. However, this does not mean that the effects of the present invention can only be achieved in these cases. In fact, good effects can be achieved at any concentration of each component between the two end values shown in the embodiments. Among the cases with better effects, the mass ratio of PQQ-2Na to subtilosin A is 0.02:0.2, 0.02:0.3 or 0.02:0.4. Some cases with poor effects in the tests are also listed in the following embodiments, such as using different components, different ratios, etc. However, the effects of these attempts are all inferior to those under the ratios described above and will not be elaborated here. The present invention will be further described below in conjunction with the embodiments: Examples 1 - 7 The mass fractions of the raw materials in Examples 1 - 7 are shown in Table 1: Table 1 Mass fractions of the raw materials in Examples 1 - 7 The preparation method includes: sequentially weighing subtilopeptin sodium, pentylene glycol, and PQQ - 2Na, adding them to water and stirring until PQQ - 2Na is completely dissolved to obtain the composition.

[0033] Comparative Examples 1 - 11 Sequentially weigh pentylene glycol, PQQ - 2Na and other components, add them to water and stir until PQQ - 2Na is completely dissolved to prepare Comparative Examples 1 - 11.

[0034] Other components include penetration enhancers: ethoxydiglycol, bis - diethoxydiglycol cyclohexane - 1,4 - dicarboxylate, emulsifiers: polysorbate - 80, polyglycerol - 10 laurate, rhamnolipid. The dosage ratios of the raw materials in Comparative Examples 1 - 11 are shown in Table 2: Table 2 Mass fractions of the raw materials in Comparative Examples 1 - 11 Efficacy verification 1. Stability experiment The solutions of Examples 1 - 4 and Comparative Examples 1 - 6 were respectively filled into 30 - ml plastic bottles, placed at 4°C and 48°C for 15 days of high - temperature investigation, and the physical and chemical indexes and appearance changes of the samples were respectively tested. The content of PQQ - 2Na in the samples before and after high - and low - temperature cycling was quantified by high - performance liquid chromatography, and the residual rate (%) of PQQ - 2Na after the stability test was calculated. The results are shown in Table 3: Table 3 Stability test results of each group Comparing Examples 1 - 4 with Comparative Examples 1 - 6, it shows that the compatibility between subtilopeptin sodium and PQQ - 2Na is very good, which can maintain the activity of PQQ - 2Na, improve the solubility of PQQ - 2Na, and make the system more stable; comparing Example 4 with Comparative Examples 1 - 6, in Comparative Example 2 (ethoxydiglycol), Comparative Example 4 (polysorbate - 80), and Comparative Example 6 (rhamnolipid), the retention rate of PQQ - 2Na at 48°C for 15 days is less than 90%, and the high - temperature compatibility with PQQ - 2Na is poor; in Comparative Example 5 (polyglycerol - 10 laurate), there is a phenomenon of polyglycerol - 10 laurate precipitation at low temperature, and the low - temperature compatibility is poor; in Comparative Example 3 (bis - diethoxydiglycol cyclohexane - 1,4 - dicarboxylate), the retention rate of PQQ - 2Na at high and low temperatures for 15 days is greater than 90%, and it has relatively good compatibility with PQQ - 2Na.

[0035] 2. Permeability experiment Sample preparation: The samples prepared in Examples 1-4 and Comparative Examples 1 and 3 were reserved; the receiving solution (PBS), ex vivo pig skin, and drug transdermal diffusion tester were used.

[0036] Experimental procedure: 1) Soak the pig skin taken out of the refrigerator in physiological saline for 5 min, and use it after the pig skin becomes soft; 2) Connect the water bath, set the parameters (37 °C, 400-600 rpm), and start preheating in advance; 3) Cut a transdermal membrane of appropriate size and place it between the two half-cells (pay attention to the direction of the skin); 4) Adjust the fixator to gradually tighten the two half-cells and the membrane; 5) Add the sample and the receiving agent solution; 6) Fix the connected two half-cells above the magnetic stirring table; 7) Set the stirring parameters and start working; 8) Take 1 mL of the receiving solution for sampling at 1, 2, 4, 6, 8, 12, and 24 h after adding the sample, and promptly supplement an equal amount of PBS; 9) After sampling, send the sample for liquid phase detection of the PQQ-2Na content, and calculate the permeability of PQQ-2Na according to the following formula.

[0037] ; Permeability % = Q n / C0 * 100% In the formula, C n represents the DPHP concentration in the permeate at the nth time point, C i represents the concentration of the analyte in the permeate at the ith time point, V s represents the volume of the receiving cell, V represents the sampling volume of the receiving solution, and S represents the effective permeation area of the diffusion cell. i = 1 to n - 1 defines the complete range of historical sampling, ensuring that when calculating the cumulative permeation amount, it includes both all the drugs taken out in the past and the remaining drugs currently, accurately reflecting the mass balance of the diffusion process.

[0038] Q n is the cumulative permeation amount, and C0 is the initial concentration of PQQ-2Na (100 mg / ml).

[0039] Comparing Examples 1-4 with Comparative Example 1, it can be seen that the permeation effect of Comparative Example 1 (only adding PQQ-2Na) is weak. Adding subtilosin A in Examples 1-4 can promote the efficient permeation and absorption of PQQ-2Na. The permeability of Example 4 (adding 0.5% subtilosin A) increased by 15 times, while the permeability of Comparative Example 3 (adding 1% bis-(diethoxydiethylene glycol cyclohexane-1,4-dicarboxylate)) only increased by 7 times. The permeation promoting effect of Example 4 is significantly better than that of Comparative Example 3.

[0040] 3. Test based on the SDS-stimulated zebrafish embryo model Take the compositions of Examples 5-7 and Comparative Examples 7-8 as the test substances for the zebrafish embryo model test: SDS-induced stimulation experiment on zebrafish embryos: The spin movement frequency of zebrafish embryos is directly related to the external stimuli they receive. Using sodium dodecyl sulfate (SDS) as a modeling agent, a zebrafish embryo stimulation model was established. Normal 24 hpf embryos were taken, and 200 μL of the mixed solution of the sample and the modeling agent was added. They were incubated in an incubator at (28.5 ± 0.5) °C for 15 min. At the same time, a blank control group, a negative control (model group), and a positive control (dipotassium glycyrrhizinate) were set up. Taking the number of embryo movements as the observation index, the soothing effect of the sample was detected. Based on the effectiveness of the experiment, when comparing the sample test group with the model group, it was found that the stimulation of the modeling agent sodium dodecyl sulfate (SDS) on zebrafish embryos could be significantly reduced, indicating that the test substance had an anti-stimulation effect at this concentration and could be used as one of the evidence supports for the evaluation of the soothing effect. The stimulation intensity was calculated using the formula: stimulation intensity = n / m × 100%, where n is the average number of spin movements of zebrafish embryos in the treatment group / time; m is the average number of spin movements of zebrafish embryos in the blank control group / time. The specific results are shown in Figure 2 。

[0041] From Figure 2 the experimental results, it can be seen that Comparative Example 7 (adding 0.4% subtilosin A) and Comparative Example 8 (only adding PQQ-2Na) both had a certain effect of reducing the stimulation of zebrafish embryos; comparing Example 7 with Comparative Examples 7-8, due to the relatively high addition concentration of subtilosin A, there was no significant change in the combination of subtilosin A and PQQ-2Na compared with their individual use; comparing Examples 5-6 with Comparative Example 8, when the content of subtilosin A decreased, it was found that the combined use of subtilosin A and PQQ-2Na could still significantly reduce the stimulation effect, indicating that the combined use of subtilosin A and PQQ-2Na had a certain soothing effect.

[0042] 4. Tyrosinase inhibition experiment and DPPH free radical scavenging experiment (1) Tyrosinase inhibition rate experiment Prepare the L-tyrosine test solution (2.550 mmol / L) for standby, and prepare the sample solutions according to Examples 5-7 and Comparative Examples 7-8 for standby. In a 96-well enzyme-linked immunosorbent assay (ELISA) plate, samples were added according to the sample blank group, sample reaction blank group, solvent blank group, and solvent reaction group, with 3 replicates in each group. First, add L-tyrosine solution, sample solution / water, and PBS buffer to each well, mix well, and react at 37 °C in the dark for 10 min. Then, add 20 μL of tyrosinase solution to each well in turn, mix well at 37 °C and react for 5 min ± 5 s, and immediately measure the absorbance at 475 nm using an ELISA reader. The addition amount per well is as shown in Table 4 below: Table 4 Calculate the tyrosinase inhibition rate according to the formula: Inhibition rate of tyrosinase = (1 - (Td - Tc) / (Tb - Ta)) × 100% (2) DPPH free radical scavenging experiment: Prepare DPPH test solution and adjust its absorbance value to about 0.7 at 517 nm at room temperature. Prepare the sample solutions of Examples 5 - 7, Comparative Example 7, and Comparative Example 8 for standby. In a 96-well microplate, add samples according to the sample group, blank group, and control group respectively. Each group has 3 replicates. After reacting in the dark for 30 min, measure the absorbance value at 517 nm using a microplate reader. The addition amount for each well is as follows: sample (sample group): 100 μL of sample solution + 100 μL of DPPH alcohol solution blank (blank group): 100 μL of sample solution + 100 μL of absolute ethanol control (control group): 100 μL of DPPH alcohol solution + 100 μL of water Calculate the DPPH free radical scavenging rate according to the formula: DPPH free radical scavenging rate = (1 - (A sample - A blank ) / A control ) × 100% Use the Bliss independence model method to calculate the combination index (CI). The calculation formula is as follows: CI = E AB / (E A + E B - E A × E B ); Among them, E AB represents the effect when the two drugs are used in combination, E A , E B represent the effects when the drugs are used alone, and E A × E B represents the expected effect when the two drugs are used in combination; when CI > 1, it indicates that the two drugs have a synergistic effect when used in combination, CI = 1 indicates that the two drugs have an additive effect when used in combination, and CI < 1 indicates that the two drugs have an antagonistic effect when used in combination. The test results of tyrosinase inhibition effect and DPPH free radical scavenging effect are calculated as shown in Table 5: Table 5 Calculation results of combination index for tyrosinase inhibition experiment and DPPD free radical scavenging experiment From the tyrosinase inhibition experiment and calculation results, it can be seen that when comparing the samples prepared in Examples 5-7 with Comparative Examples 7-8 (adding subtilopeptin sodium and PQQ-2Na alone), the combined use of drugs, such as in Examples 5-7, has a significant inhibitory effect on tyrosinase. When using PQQ-2Na and subtilopeptin sodium alone, no significant inhibitory effect is shown, and the calculated synergistic index CI > 1, indicating that the combined use of PQQ-2Na and subtilopeptin sodium has a good synergistic effect in inhibiting tyrosinase activity.

[0043] From the results of the DPPH free radical scavenging experiment, it can be seen that the DPPH free radical scavenging rates of Comparative Example 7 (adding only subtilopeptin sodium) and Comparative Example 8 (adding only PQQ-2Na) are average, and are significantly lower than those of Examples 5-7; and the synergistic index CI > 1, indicating that the combined use of PQQ-2Na and subtilopeptin sodium has a significant synergistic effect in scavenging free radicals.

[0044] In summary, after adding subtilopeptin sodium in Examples 5-7, compared with Comparative Examples 7-8, the tyrosinase inhibition rate and DPPH free radical scavenging rate are significantly improved, indicating that the synergistic antioxidant effect of subtilopeptin sodium and PQQ-2Na is significantly enhanced, and it has a whitening effect.

[0045] 5. Bacteriostatic efficacy The bacteriostatic efficacy was verified using the compositions of Examples 5-7 and Comparative Examples 7-11 as test substances.

[0046] Test bacteria and their numbers: Staphylococcus aureus ATCC 6538, Propionibacterium acnes BNCC336649 Bacterial concentration: Staphylococcus aureus ATCC 6538 3×10 6 CFU / mL, Propionibacterium acnes 9.5×10 6 CFU / mL Detection method: QB / T2738-2012 Evaluation method for antibacterial and bacteriostatic effects of daily chemical products 7.3 Detection method for bacteriostatic effects of bacteriostatic daily chemical products (suspension quantitative method). Mix the test bacterial suspension evenly, and let it act for 24h. If the bacteriostatic rate ≥ 50-90%, it indicates that the test sample has a bacteriostatic effect; if the bacteriostatic rate > 90%, it indicates that the test sample has a strong bacteriostatic effect.

[0047] Test steps: a) Appropriately dilute the test bacterial suspension 0 with PBS solution, and the required concentration is: take 0.1mL and drop it into 5.0mL of the control sample solution (PBS), and the recovered bacterial count is 1×10 4 ~9×10 4 cfu / mL.

[0048] b) Pipette 50 mL of the test sample solution into a sterilized blue-capped bottle and keep it at a constant temperature of 20 °C for 5 min.

[0049] d) Pipette 1.0 mL of the test bacterial solution into the blue-capped bottle containing 50 mL of the test sample solution, mix quickly, place it on a horizontal shaker and shake at a rate of 150 rpm, and start timing immediately.

[0050] e) After the action reaches the set time, take 0.5 mL of the test bacteria and sample mixture and add it to a test tube containing 4.5 mL of sterilized PBS, and mix well.

[0051] f) After standing for 10 min, pipette 1 mL of the sample solution (or, after appropriate dilution, take the dilution solutions of 2 - 3 dilution degrees) and place it in a sterilized petri dish. Inoculate two sterilized petri dishes for each sample solution or dilution degree. Pour 15 mL of nutrient agar medium (for bacteria) or Sabouraud agar medium (for Candida albicans) cooled to 40 °C - 45 °C. Rotate the petri dish to make it fully uniform. After the agar solidifies, invert the petri dish and incubate at 36 °C ± 1 °C for 48 h ± 2 h (for bacteria) or 72 h ± 3 h (for Candida albicans), and then perform viable bacterial colony counting.

[0052] g) Use PBS instead of the test sample and operate according to the above steps simultaneously as a control sample.

[0053] h) Calculate the antibacterial rate, and the results are shown in Table 6.

[0054] Table 6 Antibacterial Rates of the Compositions in Examples 5 - 7 and Comparative Examples 7 - 11 Use the Bliss independent model method (the formula is the same as before) to calculate the synergy index of the composition in terms of antibacterial property, and the calculation results are shown in Table 7: Table 7 Synergy Index (CI Value) of the Composition in Terms of Antibacterial Property The data shows that Comparative Example 7, Comparative Example 9, and Comparative Example 10 (only adding subtilosin A) have no inhibitory effect on Staphylococcus epidermidis. When added above 0.3% (Comparative Example 10 and Comparative Example 7), they have a certain antibacterial effect on Propionibacterium acnes. Comparative Example 8 and Comparative Example 11 (only adding PQQ-2Na and 1,2-pentanediol) have no antibacterial effect on both strains. The above results show that subtilosin A is the key component in the antibacterial composition of the present invention for inhibiting the activity of Propionibacterium acnes. Although using PQQ-2Na alone does not show a significant inhibitory effect, when used in combination with subtilosin A, it has a good synergistic effect on inhibiting Propionibacterium acnes, and as the addition amount of subtilosin A increases, the synergistic antibacterial effect of PQQ-2Na becomes more significant. And it also has a certain effect on inhibiting Staphylococcus epidermidis.

[0055] The above are only the preferred embodiments of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements should also be regarded as the protection scope of the present invention.

Claims

1. A composition containing PQQ, characterized in that, Comprising pyrroloquinoline quinone or its sodium salt and subtilosin A sodium salt; wherein the mass ratio of pyrroloquinoline quinone or its sodium salt to subtilosin A sodium salt is (0.02 - 0.1):(0.05 - 0.5).

2. The composition according to claim 1, wherein wherein the mass ratio of disodium pyrroloquinoline quinone to subtilosin A sodium salt is 0.02:(0.2 - 0.4) or 0.1:(0.05 - 0.5).

3. The composition according to claim 1, wherein wherein the mass ratio of disodium pyrroloquinoline quinone to subtilosin A sodium salt is 0.02:0.2, or 0.02:0.3, or 0.02:0.4, or 0.1:0.05, or 0.1:0.1, or 0.1:0.3, or 0.1:0.

5.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of skin care products.

5. The application according to claim 4, characterized in that The efficacy of the skin care products includes soothing, antioxidant, whitening and / or antibacterial.

6. The application according to claim 5, wherein The antibacterial includes anti-Staphylococcus aureus and / or Propionibacterium acnes.

7. Skin care product, characterized in that, It includes the composition according to claims 1 to 3 and excipients.

8. The skin care product according to claim 7, wherein wherein the mass fraction of the composition is 0.15% - 0.6%.

9. The skin care product according to claim 8, characterized in that, The excipients include pentylene glycol and water.

Images